Acid blockers are 'deadly poison' that cause cancers, autoimmune diseases, infertility, erectile dysfunction, depression, fatty liver and irritable bowel; their spread since about 2004–2005 explains a doubling of cancer and erectile dysfunction.

Original statement

خد يا بتاع الجهاز الهضمي اعرف ان مثبطات الحموضه بتجيب امراض مناعيه وسرطان وعقم وارتخى عند الرجاله >> واكتئاب | بص مثبطات الحموضه يا عبد الله في حد ذاتها سم قاتل يعني طالما مثبطات الحموضه بقت موجوده ا اعرف ا ان انت ا المرض جالك حرفيا مناعتك وقعت الام ضهرك ظهرت شعرك وقع عجزت ا عضمك اتاكل اا انسولينك طلع بالرغم ان ان انت ما بتاكلش اصلا هتتخن هتربي كرش

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Acid blockers are 'deadly poison' that cause cancers, autoimmune diseases, infertility, erectile dysfunction, depression, fatty liver and irritable bowel; their spread since about 2004–2005 explains a doubling of cancer and erectile dysfunction.

Origin

Source status

Video transcript (own words)

Attribution

Elawady (machine transcript)

Video

اتفرجوا عالبودكاست ده وقولولي رأيكوا عشان انزلكوا الحلقه التانيه منه (Open source)

Published

9 April 2026

Timestamp

not available (transcript has no timings)

Attribution uncertainty

Podcast/live-stream machine transcript. In 6T7S4CEKswY the word 'depression' follows a speaker change (>>) and may have been added by the interviewer and affirmed by Elawady. original_ar joins separate verbatim passages with ' | '.

Claimed mechanism

Not specified; general toxicity of acid suppression.

Claimed health effect

Cancer, autoimmune disease, infertility, ED, depression, fatty liver, IBS.

Population concerned

All users.

Geographic restriction by Elawady

none found

Diverging source versions

Scientific assessment

Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

Acid blockers are poison and cause cancer, autoimmune disease, infertility, ED, depression, fatty liver and IBS.

2. What is demonstrably correct?

Some cohort studies report associations of long-term PPI use with gastric cancer (Cheung 2018: HR 2.44 after H. pylori eradication) and dementia (Gomm 2016: HR 1.44); these are cited in the archive bibliography.

3. What is wrong or exaggerated?

'Deadly poison' and the list of diseases are not supported. Gastric cancer and dementia associations are observational and prone to protopathic bias and confounding; the dementia signal was not confirmed by the COMPASS RCT. No evidence was found for infertility, ED, depression or autoimmune disease as established PPI effects. Rising cancer or ED figures since 2004 are an ecological correlation without causal value.

4. What remains unclear?

Long-term (>10 years) effects on gastric cancer in specific groups remain under study.

5. Which studies support it?

A-PPI-11 (gastric cancer association), A-PPI-04 (dementia association).

6. Which studies contradict it?

COMPASS (I-PPI-01): no significant differences for cancer, dementia and other outcomes except enteric infections.

7. What applies to Germany and Europe?

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

8. What is known about Egypt?

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

9. What practical conclusion is appropriate?

Stopping an indicated PPI out of fear of these diseases is not supported by evidence and can be harmful (see C-PPI-10).

Assessment details

Rationale for certainty of evidence

Apart from an observational association with gastric cancer (one Hong Kong cohort after H. pylori eradication, absolute excess 4.29 per 10,000 person-years) and an older observational dementia signal, no evidence for these broad effects was identified; COMPASS found no excess of cancer or other outcomes over 3 years. The ecological 2004–2026 argument cannot separate PPIs from ageing, diagnosis and countless other trends.

Source quality

Video statements; no studies cited by Elawady for these outcomes.

Regional transferability

Not region-specific.

Individual exceptions

None identified.

Regional scope of the claim

general (biological/medical)

Last reviewed

25 October 2026 provisional

In plain language

Some studies found that long-term PPI users more often get stomach cancer or dementia, but such studies cannot show cause and effect. A large randomised trial did not find more cancer or dementia over three years. There is no good evidence that PPIs cause infertility, impotence, depression or autoimmune diseases, and calling them deadly poison is not accurate.

Studies on this claim

Regional context

Germany / EU

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

Egypt

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

What applies in my country?

General scientific assessment

Mostly false Mostly false: apart from uncertain observational signals, these broad harms are not supported.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study.. Cheung KS et al.. Gut 2018 · PMID 29089382 · DOI 10.1136/gutjnl-2017-314605
2. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.. Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
3. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.. Gomm W et al.. JAMA Neurol 2016 · PMID 26882076 · DOI 10.1001/jamaneurol.2015.4791